ENZN (Enzon Pharmaceuticals) COGS-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals COGS-to-Revenue?

Enzon Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

Enzon Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Enzon Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2024 was N/A%.

Enzon Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Enzon Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals COGS-to-Revenue Chart

Enzon Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

Enzon Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Enzon Pharmaceuticals COGS-to-Revenue Calculation

Enzon Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.026
	=	0.00

Enzon Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Enzon Pharmaceuticals (OTCPK:ENZN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Enzon Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Enzon Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

EZ1:Germany

Address

20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016

Website

http://www.enzon.com

Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.

Executives

Randolph C Read	director	C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone	director	C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick	director	C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper	other: See explanation of responses	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc	other: See explanation of responses	2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper	other: See explanation of responses	6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc.	other: See Footnote 1	600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp.	other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman	10 percent owner, other: See Footnote 1	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn	10 percent owner	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein	officer: VP-Finance and PFO
Jonathan Christodoro	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121